A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

Pharmacia and Upjohn24 enrolled

Overview

The purpose of this study is to see if it is safe and effective to give delavirdine mesylate (Rescriptor) plus two nucleoside reverse transcriptase inhibitors (NRTIs) to HIV-infected children and babies. This study also examines how the body processes Rescriptor when taken with 2 NRTIs.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

Conditions

HIV Infections

Interventions

Delavirdine mesylateDRUG

Eligibility

Sex: ALLMin age: 1 MonthMax age: 15 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: * HIV infection. * Plasma HIV-1 levels greater than 10,000 copies/ml.

Locations (1)

Pharmacia & Upjohn

Peapack, New Jersey, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.